|
gptkbp:instance_of
|
gptkb:chemical_compound
gptkb:Agent
|
|
gptkbp:administered_by
|
oral tablet
intravenous injection
|
|
gptkbp:affects
|
rapidly dividing cells
|
|
gptkbp:associated_with
|
cardiotoxicity
pulmonary toxicity
hemorrhagic cystitis
|
|
gptkbp:atccode
|
L01 AA01
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Cytoxan
|
|
gptkbp:can_be_combined_with
|
gptkb:vincristine
gptkb:methotrexate
gptkb:rituximab
gptkb:trastuzumab
gptkb:prednisone
gptkb:taxanes
anthracyclines
cyclophosphamide and carboplatin
cyclophosphamide and doxorubicin
cyclophosphamide and etoposide
platinum-based drugs
|
|
gptkbp:casnumber
|
6055-19-2
|
|
gptkbp:chemical_formula
|
C7 H15 Cl2 N2 O2 P
|
|
gptkbp:contraindication
|
pregnancy
active infections
severe bone marrow suppression
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cyclophosphamide
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:dexamethasone
mesna
|
|
gptkbp:investment
|
secondary malignancies
|
|
gptkbp:mechanism_of_action
|
gptkb:Agent
alkylation of DNA
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
gptkb:ifosfamide
gptkb:busulfan
gptkb:chlorambucil
|
|
gptkbp:side_effect
|
nausea
vomiting
hair loss
bone marrow suppression
bladder toxicity
|
|
gptkbp:used_for
|
gptkb:cancer_treatment
autoimmune diseases
|
|
gptkbp:used_in
|
immunosuppressive therapy
chemotherapy regimens
|
|
gptkbp:bfsParent
|
gptkb:Lenalidomide
gptkb:methotrexate
|
|
gptkbp:bfsLayer
|
5
|